Pharma | Partner with us
Combination drug discovery
Identifying and optimising combination strategies to improve therapeutic outcomes, minimise side effects and reduce drug dosage for patients
Efficiency and strength
Many rare diseases exhibit a broad range of symptoms and causes, meaning drug combinations have better therapeutic outcomes than single-drug treatments. However, that can leave millions of potential combinations to test. In addition to predicting the synergy between therapeutic candidates and other compounds, our algorithms rank and prioritise the combinations for further experimental validation.
Our AI can comb through data at a massive scale and empowers human experts with the best results from its discoveries. To rank and prioritise the combinations we discover in silico, our AI platform first identifies and screens the billions of possible combinations against its public and proprietary dataset, from which it “learns” and predicts completely novel combinations. Our drug discovery experts then establish a pharmacological rationale and carefully select the most promising combinations for further validation.
Partner with us
We also have the means for preclinical development and can manage preclinical validation on behalf of (or in collaboration with) our pharma partners. If you’re interested in a combination therapy partnership, please contact our business development team at firstname.lastname@example.org .Contact us